Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomePreferred Dividend PaymentsProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Benitec Biopharma (BNTC) Operating Expenses (2019 - 2025)

Historic Operating Expenses for Benitec Biopharma (BNTC) over the last 7 years, with Q2 2025 value amounting to $9.8 million.

  • Benitec Biopharma's Operating Expenses rose 7725.31% to $9.8 million in Q2 2025 from the same period last year, while for Jun 2025 it was $41.8 million, marking a year-over-year increase of 8570.48%. This contributed to the annual value of $41.8 million for FY2025, which is 8570.48% up from last year.
  • Benitec Biopharma's Operating Expenses amounted to $9.8 million in Q2 2025, which was up 7725.31% from $15.3 million recorded in Q1 2025.
  • Benitec Biopharma's Operating Expenses' 5-year high stood at $15.3 million during Q1 2025, with a 5-year trough of $3.5 million in Q1 2022.
  • For the 5-year period, Benitec Biopharma's Operating Expenses averaged around $6.1 million, with its median value being $4.8 million (2021).
  • Its Operating Expenses has fluctuated over the past 5 years, first tumbled by 753.82% in 2022, then surged by 27032.12% in 2025.
  • Quarter analysis of 5 years shows Benitec Biopharma's Operating Expenses stood at $4.9 million in 2021, then grew by 15.72% to $5.6 million in 2022, then grew by 23.17% to $6.9 million in 2023, then skyrocketed by 55.98% to $10.8 million in 2024, then dropped by 8.99% to $9.8 million in 2025.
  • Its last three reported values are $9.8 million in Q2 2025, $15.3 million for Q1 2025, and $10.8 million during Q4 2024.